Global Gastroretentive Drug Delivery Systems Market by Type (Liquid, Tablets, Capsule) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

Summary of the Report

Global gastroretentive drug delivery system market was valued at USD 11.8 Billion in 2020. It is projected to grow at a 6.4% compound annual growth rate (CAGR), between 2021 and 2028. Market growth is expected to be boosted by pharmaceutical companies that are adapting to changing needs and investing in gastroretentive drugs delivery systems (DDSs). Market growth is expected to be accelerated by the rising incidence of disease in the world and the proven efficacy and safety of gastroretentive drug delivery system for treating several gastric-related conditions such as gastric ulcer and peptic ulcer.

Due to restrictions in production during mid-2020, the market for gastroretentive drugs delivery systems suffered a slight impact from the COVID-19 pandemic. However, the restraint effect was countered by growing demand, online prescriptions and e-pharmacy. Due to Japan's well-established healthcare infrastructure, the market was not affected by COVID-19.

Helicobacter Pylori infection is the most prevalent human infection worldwide. According to an article by the University of Arizona H.pylori infection rates are higher in developing countries then they are in developed countries. In developing countries, the incidence of new infections is between 3 and 10% and 0.5% in developed countries. H. Pylori infection can cause gastric cancer, gastroduodenal ulcer disease and gastritis. The management and prevention of this disorder can be done by increasing mucosal protection, and decreasing gastric acidity. Gastroretentive drug delivery methods increase the gastric retention time. This aggregates the drug concentration at the application site. This may reduce essential dosage or improve its bioavailability. Globally, H. pylori is increasing in prevalence. This will likely increase the demand for gastroretentive delivery systems.

Gastroretentive Drug Delivery technology (GRDD), has been developed to allow for controlled delivery of therapeutic molecules. This increases bioavailability. Technological and scientific advances have been made in the research and development of rate-controlled oral drug delivery methods. This is achieved by overcoming physiological challenges such as unpredictable gastric emptying times or short gastric residence time. GRDDS could be used to improve oral drug delivery. Extended retention in the upperGI tract can increase oral bioavailability and therapeutic outcomes.

Current technological and scientific advances are made to rate-control oral drug delivery systems. They overcome physiological problems such as unpredictable gastric emptying times and short gastric residence time. To overcome these difficulties, the gastroretentive delivery system for drug delivery is designed to prolong gastric retention and increase drug absorption.

Type Insights

In 2020, the floating drug delivery system segment was responsible for 46.0% of the total revenue. Floating drug delivery is one way to achieve gastric retention and adequate drug bioavailability. This system is less bulky than other gastric fluids, and therefore stays buoyant in your stomach for a longer period of time without affecting gastric emptying. This system allows the drug to be released slowly at a preferable rate. The stomach is empty of the drug residue after it has been released. This increases gastric retention and allows for better control of fluctuations in plasma drug concentrations, thereby enhancing segmental growth.

Over the forecast period, the segment of bioadhesive drug-delivery systems is expected to experience a healthy CAGR at 7.1%. The bioadhesive polymers can be used to enhance drug absorption. They are able to adhere to the stomach's epithelial surface. They also prolong the gastric retention and increase its adoption rate.

Distribution channel Insights

Hospital pharmacies dominated the market for gastroretentive drugs delivery systems in 2020 and accounted for 34.9% of the total revenue. Hospital pharmacies keep stock of products for gastric disorders in-patients as well as out-patients. Segmental growth is expected to be fueled by increased investments in healthcare infrastructure, and rising consumer awareness in developing and underdeveloped countries.

Online pharmacies are expected to grow at 7.7% annually over the forecast period. Online pharmacies offer convenience and easy access to customers in terms of delivery and prices. These pharmacies also offer discounts on a certain amount of products or bundle pricing for gastric-related items, which helps to secure market growth.

Insights from the Dosage Form

In 2020, 38.5% of the market share for gastroretentive drug delivery system products was held by tablets. Manufacturers are expected to continue their strong market position by focusing on gastroretentive tablet development. Lupin is developing bioadhesive tablets under the brand name Xifaxan. Patients find it more appealing because the tablets have a lower density than stomach fluid. This causes buoyancy in gastric fluid.

In 2020, the capsule dosage form segment accounted for a significant revenue share. Due to their improved efficiency, many key players are producing capsule-based gastroretentives. Pfizer and Roche are producing controlled-release capsules as well as bilayer floating capsules. Different geometrical forms can be compressed into capsules. This allows for a variety of dosage forms, depending on the size of the biodegradable polymer, and encourages segmental expansion.

Regional Insights

North America was the market leader in gastroretentive drugs delivery systems and had the largest revenue share at 41.2% in 2020. North America's top market share was due to its high gastric cancer prevalence, rising R&D spending, and growing initiatives by market players in Canada and the U.S. in developing advanced gastroretentive drugs delivery systems. Regional growth will be encouraged by better adoption of gastroretentive drug delivery systems and the follow-up of advanced healthcare treatment methods. GRDDS are expected to be in demand due to the longer retention time of drugs in the stomach.

In 2020, the Asia Pacific region was responsible for a significant share of revenue. The forecast period sees the market growing at 6.8% annually. These devices will be in high demand due to the large patient population. Regional market growth is expected to be driven by rising research and development spending in emerging countries like Japan and Singapore. Global players want to launch new products in the region to meet this growing demand.

The market in Europe is forecast to grow at a rate of 27.2% over the forecast period. The region's growth is expected to be aided by improvements in healthcare infrastructure and increased research activity in the healthcare sector. The rise in health care spending in countries like France, Germany and other European countries is due to a rise of private health insurance, as well as the entry of international drug producers and providers. The European GRDDS market is expected to grow in size.

Market Share Insights & Key Companies

To maintain their market share, market players use a variety of strategies to keep their market share. These include product launch, strategic acquisitions and innovation. The market leaders in gastroretentive drugs delivery systems (DDSs), include:

• F. Hoffmann La Roche

• Ranbaxy

• GlaxoSmithKline

• Pharmacia

• Depomed

• Alcon, Inc.

• Lupin

• Galanix

• Sun Pharma

Up Market Research published a new report titled “Gastroretentive Drug Delivery Systems Market research report which is segmented by Type (Liquid, Tablets, Capsule), By Players/Companies Sun Pharma, Ranbaxy, GlaxoSmithKline, Lupin, Pharmacia, Alcon Inc, F Hoffmann La Roche, Depomed, Galanix”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.

Report Scope

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.

Global Gastroretentive Drug Delivery Systems Market Report Segments:

The market is segmented by Type (Liquid, Tablets, Capsule).

Gastroretentive Drug Delivery Systems Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

Key Benefits for Industry Participants & Stakeholders:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Gastroretentive Drug Delivery Systems Market

Overview of the regional outlook of the Gastroretentive Drug Delivery Systems Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.

Highlights of The Gastroretentive Drug Delivery Systems Market Report:

1. The market structure and projections for the coming years.
2. Drivers, restraints, opportunities, and current trends of Gastroretentive Drug Delivery Systems Market.
3. Historical data and forecast.
4. Estimations for the forecast period 2028.
5. Developments and trends in the market.

                1. Liquid

                2. Tablets

                3. Capsule

7. Market scenario by region, sub-region, and country.
8. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
9. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
10. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Gastroretentive Drug Delivery Systems Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

How you may use our products:

• Correctly Positioning New Products
• Market Entry Strategies
• Business Expansion Strategies
• Consumer Insights
• Understanding Competition Scenario
• Product & Brand Management
• Channel & Customer Management
• Identifying Appropriate Advertising Appeals

Reasons to Purchase the Gastroretentive Drug Delivery Systems Market Report:

• The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
• Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
• Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
• The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
• Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.